*礼来公司的瑞他曲肽在3期临床试验中，80周内平均减重20.8%*礼来公司将于2027年第一季度提交瑞他曲肽的生物制品许可申请$LLY
*LILLY'S RETATRUTIDE CUTS WEIGHT AVG 20.8% OVER 80 WKS IN PH. 3*ELI LILLY - TO SUBMIT BIOLOGICS LICENSE APPLICATION FOR RETATRUTIDE IN Q1 2027$LLY
*LILLY'S RETATRUTIDE CUTS WEIGHT AVG 20.8% OVER 80 WKS IN PH. 3*ELI LILLY - TO SUBMIT BIOLOGICS LICENSE APPLICATION FOR RETATRUTIDE IN Q1 2027$LLY